D. Western Therapeutics Institute, Inc.
Regarding U.S. Distribution Partnership and Launch Timing for Bondlido
Announcement on the U.S. distribution partnership and launch timing for Bondlido. Discussions with Terrain Pharmaceuticals are ongoing, with a U.S. distribution license agreement expected to be signed within 2026. The initial shipment is scheduled for delivery in November 2026. Revenue recognition will depend on contract terms; at this time the impact on the fiscal year ending December 2026 earnings guidance is undetermined.
Key Figures
- Timing of Bondlido distribution license agreement signing: within 2026
- Initial shipment delivery timing: November 2026
- Impact on fiscal year ending December 2026 earnings guidance: Undetermined
AI要約
Key Points on Partnership and Launch Timing
A distribution partnership with Terrain Pharmaceuticals for Bondlido's U.S. market rollout is progressing, with the agreement expected to be finalized within 2026. The initial shipment is scheduled to be delivered to Terrain in November. Finalization of contract terms will take additional time, and reviews of distribution channels and supply plans are ongoing.
Financial Impact and Outlook
Revenue from this product under this arrangement will depend on the finalized contract terms, and may result in revenue-sharing receipts; however, the impact on the fiscal year ending December 2026 earnings guidance is currently undetermined. The company will disclose any material impact promptly once confirmed.
D. Western Therapeutics Institute, Inc.
Company overview · Stock price · Financial data · All IR
